Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?

Since the appearance of coronavirus disease 2019 (COVID-19), numerous studies have been conducted to find effective therapeutics. Favipiravir (FVP) is one of the repurposed drugs which has been authorized in a few countries on an emergency basis to treat COVID-19. Elderly individuals especially 65 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Henrietta, Lanszki, Zsófia, Keserű, György M., Jakab, Ferenc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091543/
https://www.ncbi.nlm.nih.gov/pubmed/35543795
http://dx.doi.org/10.1007/s11357-022-00582-8
_version_ 1784704945068441600
author Papp, Henrietta
Lanszki, Zsófia
Keserű, György M.
Jakab, Ferenc
author_facet Papp, Henrietta
Lanszki, Zsófia
Keserű, György M.
Jakab, Ferenc
author_sort Papp, Henrietta
collection PubMed
description Since the appearance of coronavirus disease 2019 (COVID-19), numerous studies have been conducted to find effective therapeutics. Favipiravir (FVP) is one of the repurposed drugs which has been authorized in a few countries on an emergency basis to treat COVID-19. Elderly individuals especially 65 years or older are more prone to develop severe illness. We aim to provide a short summary of the current knowledge of the antiviral efficacy of favipiravir with respect to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–infected elderly patients. We found that it is rather controversial whether favipiravir is effective against SARS-CoV-2 infection. Data regarding patients 65 years or older is not sufficient to support or reject the usage of favipiravir for COVD-19 treatment. Further studies would be advisable to elicit the efficiency of favipiravir in elderly COVID-19 patients.
format Online
Article
Text
id pubmed-9091543
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-90915432022-05-11 Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19? Papp, Henrietta Lanszki, Zsófia Keserű, György M. Jakab, Ferenc GeroScience Short Communication Since the appearance of coronavirus disease 2019 (COVID-19), numerous studies have been conducted to find effective therapeutics. Favipiravir (FVP) is one of the repurposed drugs which has been authorized in a few countries on an emergency basis to treat COVID-19. Elderly individuals especially 65 years or older are more prone to develop severe illness. We aim to provide a short summary of the current knowledge of the antiviral efficacy of favipiravir with respect to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–infected elderly patients. We found that it is rather controversial whether favipiravir is effective against SARS-CoV-2 infection. Data regarding patients 65 years or older is not sufficient to support or reject the usage of favipiravir for COVD-19 treatment. Further studies would be advisable to elicit the efficiency of favipiravir in elderly COVID-19 patients. Springer International Publishing 2022-05-11 /pmc/articles/PMC9091543/ /pubmed/35543795 http://dx.doi.org/10.1007/s11357-022-00582-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Short Communication
Papp, Henrietta
Lanszki, Zsófia
Keserű, György M.
Jakab, Ferenc
Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?
title Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?
title_full Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?
title_fullStr Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?
title_full_unstemmed Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?
title_short Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?
title_sort favipiravir for the treatment of covid-19 in elderly patients—what do we know after 2 years of covid-19?
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091543/
https://www.ncbi.nlm.nih.gov/pubmed/35543795
http://dx.doi.org/10.1007/s11357-022-00582-8
work_keys_str_mv AT papphenrietta favipiravirforthetreatmentofcovid19inelderlypatientswhatdoweknowafter2yearsofcovid19
AT lanszkizsofia favipiravirforthetreatmentofcovid19inelderlypatientswhatdoweknowafter2yearsofcovid19
AT keserugyorgym favipiravirforthetreatmentofcovid19inelderlypatientswhatdoweknowafter2yearsofcovid19
AT jakabferenc favipiravirforthetreatmentofcovid19inelderlypatientswhatdoweknowafter2yearsofcovid19

Ejemplares similares